** Shares of heart valve maker Anteris Technologies rise as much as 6.8%; last up 4.2% at $5.84 in early trading
** Wall Street brokerages start coverage of AVR as IPO research quiet period comes to an end
** Barclays initiates coverage with "overweight" rating and $22 PT, a 292.2% upside to stock's last close
** Brokerage says AVR's transcatheter aortic valve replacement (TAVR) platform is positioned to capture 4%-5% of the U.S. TAVR market
** Adds that the timing for AVR's entry into TAVR could not look better
** TD Cowen initiates coverage with "buy" rating and $15 PT, a 167.4% upside to stock's last close
** Brokerage says AVR's TAVR platform has disruptive potential that fills unmet needs in the industry
** Adds that AVR should capture meaningful share in the ~$10 bln TAVR market
** TD Cowen, Barclays and Cantor were the joint book-running managers for AVR's IPO
** As of last close, AVR shares down 6.5% since Nasdaq debut on Dec. 13
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.